iHuman Inc. American depositary shares each representing five Class A ordinary shares (IH) fair value
Consumer Defensive · Education & Training Services · NYSE · United States
$1.14+0.00%
Market cap $58MNext earnings 2025-06-27Updated Oct 18, 2026
Our verdict
Trades 68% below our fair value
Price
$1.14
Model fair valueConfidence: low
about $3.55
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a growth company: P/E comparison.
ACCE opinioniHuman Inc. American depositary shares each representing five Class A ordinary shares (IH)
Fair value (2 models)
Not available
ACCE price target
$0.93
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $1.14 at the close on 23 Oct 2026, 22:00 CEST.
Models: P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
37
out of 100
Analysts
100% buy
1 covering
P/E
19.0x
forward 58.8x
1-year return
-59.1%
Dividend yield
0.00%
iHuman Inc. American depositary shares each representing five Class A ordinary shares in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
iHuman Inc. (IH) runs online and offline education programs in China, with a gross margin of 66.8% that points to a high-margin content and services model. The business is shrinking, though: revenue fell 13.4% and the operating margin sits at -12.0%, so the company is losing money on operations. At a $58M market cap and a trailing P/E of 19.0, the earnings figure looks flattering next to a forward P/E of 58.8, which implies profits are expected to fall sharply. ROE of 2.6% and a composite score of 37/100 leave little to recommend the name on fundamentals alone. It is not in any index, so the case for a deeper look would have to rest on a turnaround that the numbers do not yet show.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Revenue and earnings falling
Revenue is down 13.4% year on year and earnings down 82.3%, with operating margin at -12.0%. The business is shrinking at the operating line despite a 66.8% gross margin.
high
Score down sharply in 90 days
ACCE score fell from 48 to 37 over 90 days, with momentum scoring just 17/100. The deterioration is recent and sustained.
moderate
Thin institutional ownership
Institutional ownership is 0.6% and insider ownership is 0.0%. With a $59M market cap, the shares have little sponsorship and may be illiquid.
AI research notes
AI-assisted·How I use AIWritten Oct 13, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Free cash flow over the last 12 months reached $45M, and the company carries almost no debt against equity.
Revenue grew 8.7% per year on average over five years, showing a longer record of expansion than the latest year suggests.
Why it could disappoint
Revenue fell 13.4% in the latest year, reversing the longer growth trend and raising doubts about near-term demand.
Forward earnings of 58.8x sit far above the sector median of 18.0x, so the stock looks expensive on expected profits.
Return on equity of 2.6% and a net margin of 3.1% show thin profitability for every dollar of capital invested.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where IH's valuation models land
Price
$1.14
Model fair valueConfidence: low
about $3.55
Model
Fair value
Upside
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
+Quarter-over-quarter institutional position changes
+Every insider and Congress trade, with how late it was disclosed
+Active 13D activist filings and top holders
Compare
Where it sits vs peers
News and Record
Press releases mentioning this company
Recent performance
1 week
-1.7%
1 month
-3.4%
3 months
-21.4%
6 months
-33.3%
YTD
-45.7%
1 year
-59.1%
SEC filings
Recommendation history, last 12 months
Date
Type
New
Previous
Price
15 Oct 2026, 00:00 CEST
ACCE price target
$0.93
first publication
$1.19
9 Sept 2026, 00:00 CEST
Fair value
$0.82
$0.84
$1.22
3 Sept 2026, 00:00 CEST
Fair value
$0.84
$0.94
$1.23
1 Sept 2026, 00:00 CEST
Fair value
$0.94
$0.72
$1.38
19 Aug 2026, 00:00 CEST
Fair value
$0.72
first publication
$1.32
Price
-59.0% · 1Y
Ask anything about IH
Answered from iHuman Inc. American depositary shares each representing five Class A ordinary shares fundamentals + recent valuations. Every number shows its source and date.
This stock Peer Peer median weaker → stronger
P/Ebetter than 0% of peers
low 0.0x19.0xhigh 19.0x
ROEbetter than 67% of peers
low -440%3%high 35%
Div yieldbetter than 83% of peers
low 0.0%0.0%high 4.3%
Peers
Prices Oct 23, 2026
Company
Price
Fair value
vs fair value
P/E
ROE
Quality
Score
IHiHuman Inc. American depositary shares each representing five Class A ordinary shares